Reviewed listing: NASDAQ:STOK · Analysis dated Oct 22, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Stoke is developing RNA medicines intended to help the body produce more of proteins that are missing. Its lead program is Zorevunersen for Dravet syndrome; there is not yet an approved commercial product.
What supports the business?
The pivotal study included the planned main cohort. Biogen is participating in development, and coordination with the FDA makes the intended approval pathway more concrete.
What could improve?
If the controlled study shows a clear benefit and approval is obtained, Stoke could sell the drugs itself and receive royalty payments from overseas sales. These revenues are not yet assured.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
25.68 USD is close to the strong case in our own development model. The middle-case calculation yields 13.48 USD; with a margin of safety, the model-dependent limit is 12.00 USD.
What is the main risk?
The pivotal study data are not expected until 2027. Disappointing efficacy, safety problems, or delays could sharply reduce the project’s value and make additional share issuance necessary.
What is the overall assessment?
Watch: Stoke is developing a possible new treatment for Dravet syndrome. Clinical progress has been demonstrated, but the pivotal study and approval are still pending. The share price already anticipates substantial commercial success.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · api-v4.fcsapi.com · Oct 21, 2026
- Original source 2 · www.sec.gov · Aug 03, 2026
- Original source 3 · www.sec.gov · Aug 03, 2026
- Original source 4 · www.sec.gov · Aug 03, 2026
- Original source 5 · stoketherapeutics.gcs-web.com · Oct 05, 2026
- Original source 6 · investor.stoketherapeutics.com · Oct 12, 2026